161 related articles for article (PubMed ID: 31887449)
1. How Do We Treat Inflammatory Bowel Diseases to Aim For Endoscopic Remission?
Dulai PS; Jairath V
Clin Gastroenterol Hepatol; 2020 May; 18(6):1300-1308. PubMed ID: 31887449
[TBL] [Abstract][Full Text] [Related]
2. Limited uptake of ulcerative colitis "treat-to-target" recommendations in real-world practice.
Bryant RV; Costello SP; Schoeman S; Sathananthan D; Knight E; Lau SY; Schoeman MN; Mountifield R; Tee D; Travis SPL; Andrews JM
J Gastroenterol Hepatol; 2018 Mar; 33(3):599-607. PubMed ID: 28806471
[TBL] [Abstract][Full Text] [Related]
3. Treat to target in inflammatory bowel disease: a survey of treatment strategies amongst Portuguese doctors.
Bernardo S; Fernandes SR; Araújo-Correia L
Rev Esp Enferm Dig; 2019 Aug; 111(8):593-597. PubMed ID: 31190548
[TBL] [Abstract][Full Text] [Related]
4. Treat-to-Target in Inflammatory Bowel Diseases, What Is the Target and How Do We Treat?
Agrawal M; Colombel JF
Gastrointest Endosc Clin N Am; 2019 Jul; 29(3):421-436. PubMed ID: 31078245
[TBL] [Abstract][Full Text] [Related]
5. Higher Adalimumab Levels Are Associated with Histologic and Endoscopic Remission in Patients with Crohn's Disease and Ulcerative Colitis.
Yarur AJ; Jain A; Hauenstein SI; Quintero MA; Barkin JS; Deshpande AR; Sussman DA; Singh S; Abreu MT
Inflamm Bowel Dis; 2016 Feb; 22(2):409-15. PubMed ID: 26752470
[TBL] [Abstract][Full Text] [Related]
6. Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease.
Zittan E; Kelly OB; Kirsch R; Milgrom R; Burns J; Nguyen GC; Croitoru K; Van Assche G; Silverberg MS; Steinhart AH
Inflamm Bowel Dis; 2016 Mar; 22(3):623-30. PubMed ID: 26829408
[TBL] [Abstract][Full Text] [Related]
7. Understanding Endoscopic Disease Activity in IBD: How to Incorporate It into Practice.
Christensen B; Rubin DT
Curr Gastroenterol Rep; 2016 Jan; 18(1):5. PubMed ID: 26759147
[TBL] [Abstract][Full Text] [Related]
8. Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus.
Vuitton L; Peyrin-Biroulet L; Colombel JF; Pariente B; Pineton de Chambrun G; Walsh AJ; Panes J; Travis SP; Mary JY; Marteau P
Aliment Pharmacol Ther; 2017 Mar; 45(6):801-813. PubMed ID: 28112419
[TBL] [Abstract][Full Text] [Related]
9. Objective Disease Monitoring Strategies from a Tertiary Inflammatory Bowel Disease Center in Hungary.
Lontai L; Kürti Z; Gonczi L; Komlódi N; Balogh F; Iliás Á; Lakatos PL
Turk J Gastroenterol; 2023 May; 34(5):508-515. PubMed ID: 36620930
[TBL] [Abstract][Full Text] [Related]
10. Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review.
Colombel JF; D'haens G; Lee WJ; Petersson J; Panaccione R
J Crohns Colitis; 2020 Feb; 14(2):254-266. PubMed ID: 31403666
[TBL] [Abstract][Full Text] [Related]
11. The prevalence of irritable bowel syndrome-type symptoms in paediatric inflammatory bowel disease, and the relationship with biochemical markers of disease activity.
Diederen K; Hoekman DR; Hummel TZ; de Meij TG; Koot BG; Tabbers MM; Vlieger AM; Kindermann A; Benninga MA
Aliment Pharmacol Ther; 2016 Jul; 44(2):181-8. PubMed ID: 27110920
[TBL] [Abstract][Full Text] [Related]
12. Treat to Target in Inflammatory Bowel Disease: An Updated Review of Literature.
Darr U; Khan N
Curr Treat Options Gastroenterol; 2017 Mar; 15(1):116-125. PubMed ID: 28161818
[TBL] [Abstract][Full Text] [Related]
13. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.
Peyrin-Biroulet L; Sandborn W; Sands BE; Reinisch W; Bemelman W; Bryant RV; D'Haens G; Dotan I; Dubinsky M; Feagan B; Fiorino G; Gearry R; Krishnareddy S; Lakatos PL; Loftus EV; Marteau P; Munkholm P; Murdoch TB; Ordás I; Panaccione R; Riddell RH; Ruel J; Rubin DT; Samaan M; Siegel CA; Silverberg MS; Stoker J; Schreiber S; Travis S; Van Assche G; Danese S; Panes J; Bouguen G; O'Donnell S; Pariente B; Winer S; Hanauer S; Colombel JF
Am J Gastroenterol; 2015 Sep; 110(9):1324-38. PubMed ID: 26303131
[TBL] [Abstract][Full Text] [Related]
14. Real-world clinical, endoscopic and radiographic efficacy of vedolizumab for the treatment of inflammatory bowel disease.
Kotze PG; Ma C; Almutairdi A; Al-Darmaki A; Devlin SM; Kaplan GG; Seow CH; Novak KL; Lu C; Ferraz JGP; Stewart MJ; Buresi M; Jijon H; Mathivanan M; Heatherington J; Martin ML; Panaccione R
Aliment Pharmacol Ther; 2018 Sep; 48(6):626-637. PubMed ID: 30063077
[TBL] [Abstract][Full Text] [Related]
15. Bone density improves with disease remission in patients with inflammatory bowel disease.
Reffitt DM; Meenan J; Sanderson JD; Jugdaohsingh R; Powell JJ; Thompson RP
Eur J Gastroenterol Hepatol; 2003 Dec; 15(12):1267-73. PubMed ID: 14624148
[TBL] [Abstract][Full Text] [Related]
16. INTERACTIONS AMONG INTERLEUKIN-6, C-REACTIVE PROTEIN AND INTERLEUKIN-6 (-174) G/C POLYMORPHISM IN THE PATHOGENESIS OF CROHN'S DISEASE AND ULCERATIVE COLITIS.
Takač B; Mihaljević S; Glavaš-Obrovac L; Kibel A; Suver-Stević M; Canecki-Varžić S; Samardžija M; Rajkovac I; Kovač D; Štefanić M
Acta Clin Croat; 2020 Mar; 59(1):67-80. PubMed ID: 32724277
[TBL] [Abstract][Full Text] [Related]
17. Definition and evaluation of mucosal healing in clinical practice.
Mazzuoli S; Guglielmi FW; Antonelli E; Salemme M; Bassotti G; Villanacci V
Dig Liver Dis; 2013 Dec; 45(12):969-77. PubMed ID: 23932331
[TBL] [Abstract][Full Text] [Related]
18. Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort.
Plevris N; Chuah CS; Allen RM; Arnott ID; Brennan PN; Chaudhary S; Churchhouse AMD; Din S; Donoghue E; Gaya DR; Groome M; Jafferbhoy HM; Jenkinson PW; Lam WL; Lyons M; Macdonald JC; MacMaster M; Mowat C; Naismith GD; Potts LF; Saffouri E; Seenan JP; Sengupta A; Shasi P; Sutherland DI; Todd JA; Veryan J; Watson AJM; Watts DA; Jones GR; Lees CW
J Crohns Colitis; 2019 Sep; 13(9):1111-1120. PubMed ID: 30768123
[TBL] [Abstract][Full Text] [Related]
19. Mesalamine in the Initial Therapy of Ulcerative Colitis.
Chibbar R; Moss AC
Gastroenterol Clin North Am; 2020 Dec; 49(4):689-704. PubMed ID: 33121689
[TBL] [Abstract][Full Text] [Related]
20. Clinical implications of mucosal healing in the management of patients with inflammatory bowel disease.
Orlando A; Guglielmi FW; Cottone M; Orlando E; Romano C; Sinagra E
Dig Liver Dis; 2013 Dec; 45(12):986-91. PubMed ID: 23993738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
